Intranasal mask for protecting the respiratory tract against viral aerosols

share:

Brief intro:

  • Author: Xiaoming Hu, Shuang Wang, Shaotong Fu, Meng Qin, Chengliang Lyu, Zhaowen Ding, Yan Wang, Yishu Wang, Dongshu Wang, Li Zhu, Tao Jiang, Jing Sun, Hui Ding, Jie Wu, Lingqian Chang, Yimin Cui, Xiaocong Pang, Youchun Wang, Weijin Huang, Peidong Yang, Limin Wang, Guanghui Ma & Wei Wei
  • Journal: Nature Communications
  • Doi: https://www.doi.org/10.1038/s41467-023-44134-w
  • Publication Date: 2023 Dec 18

Products/Services used in the paper

Quotation shows PackGene:pLV.CMV.hACE2.PGK.Puro.WPRE (human ACE2-plasmid) was purchased from PackGene Biotech

Research Field:coronavirus 2

AAV Serotype:plasmid

Request Quote

Abstract

The spread of many infectious diseases relies on aerosol transmission to the respiratory tract. Here we design an intranasal mask comprising a positively-charged thermosensitive hydrogel and cell-derived micro-sized vesicles with a specific viral receptor. We show that the positively charged hydrogel intercepts negatively charged viral aerosols, while the viral receptor on vesicles mediates the entrapment of viruses for inactivation. We demonstrate that when displaying matched viral receptors, the intranasal masks protect the nasal cavity and lung of mice from either severe acute respiratory syndrome coronavirus 2 or influenza A virus. With computerized tomography images of human nasal cavity, we further conduct computational fluid dynamics simulation and three-dimensional printing of an anatomically accurate human nasal cavity, which is connected to human lung organoids to generate a human respiratory tract model. Both simulative and experimental results support the suitability of intranasal masks in humans, as the likelihood of viral respiratory infections induced by different variant strains is dramatically reduced.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download